Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase 2, Double-blind, Placebo-controlled, Parallel-group, 2-arm Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous Lunsekimig in Adult Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)

NCT06454240 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT06454240
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06454240 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase 2, Double-blind, Placebo-controlled, Parallel-group, 2-arm Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous Lunsekimig in Adult Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
Lead sponsor
Sanofi
Phase
Phase 2
Overall status
Completed
Start date
July 17, 2024
Completion date
April 23, 2026
Enrollment
79 (actual)
Sites
29

Conditions

As the registry lists them; a condition with its own page is linked.

chronic rhinosinusitis with nasal polyps